Navigation Links
Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
Date:6/9/2009

-Second Data Set Presented at MDS-

PARIS, June 9 /PRNewswire/ -- Results from three placebo controlled studies conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set presented at the Movement Disorder Society (MDS) 13th Annual International Congress in Paris, France. The studies were sponsored by Merz Pharmaceuticals, which plans to file a Biologic License Application (BLA) for NT-201 in the USA in the near future.

The NT-201 data presented at the Movement Disorder Society's annual meeting includes the following three abstracts: Efficacy and safety of NT-201 (Xeomin(R); botulinum neurotoxin type A free from complexing proteins) in pre-treated cervical dystonia patients, Efficacy and safety of NT-201 (Xeomin; botulinum neurotoxin type A free from complexing proteins) in treatment-naive cervical dystonia patients, and Repeated injections of NT-201 (Xeomin; botulinum neurotoxin type A free from complexing proteins) in upper limb spasticity patients.

Eric Pappert, M.D., Vice President of Medical Affairs, Merz Pharmaceuticals, USA said, "These findings suggest Xeomin, the brand name for NT-201 in Europe, may be a new option in the treatment of movement disorders in the United States."

First Study -Title

Efficacy and safety of NT-201 (Xeomin(R), botulinum neurotoxin type A free from complexing proteins) in pre-treated cervical dystonia patients authored by Susanne Grafe, Cynthia Comella, Joseph Jankovic, Daniel Truong, and Angelika Hanschman.

Method

CD patients previously treated with another brand of BoNTA were randomized to placebo, 120 U NT 201, or 240 U NT-201. Following injection, patients were evaluated at 4 weeks using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). Adverse events (AEs) were also collected up to 20 weeks or until the next injection. The change from Baseline to week 4 for the TWSTRS scores was analyzed using an ANCOVA model.

Results

There were 143 CD patients (65% women, mean age 53.9 years, mean CD duration 83.3 months), Patients were randomized to placebo (N= 46), 120 U NT 201 (N= 47), and 240U NT 201 (N= 50). The change in total TWSTRS from baseline to week 4 was -2.4 plus or minus 8.1 points (placebo group); -8.5 plus or minus 9.7 points (120 U group) and -11.4 plus or minus 13.1 points ( 240 U group) (p < 0.002 compared to placebo). Improvement in TWSTRS-Severity score from baseline to week 4 was -1.9 plus or minus 3.7 points (placebo group); -3.7 plus or minus 4.4 points (120 U group) and -5.6 plus or minus 6.4 points ( 240 U group) . AEs occurred in 34.8% of patients of the placebo group, 55.3% of the 120 U group and 46.0% of the 240 U group. AEs reported most frequently were dysphagia (4.3% vs 8.5% vs 16.0%), neck pain (4.3% vs 8.5%, vs 10.0%), and injection site pain (2.2% vs 8.5% vs 2.0%) for each group, respectively.

Second Study - Title

Efficacy and safety of NT-201 (Xeomin(R); Botulinum neurotoxin type A free from complexing proteins) in treatment-naive cervical dystonia patients authored by Susanne Grafe, Cynthia Comella, Joseph Jankovic, Daniel Truong, and Angelika Hanschman.

Method

CD patients not previously treated with BoNT were randomized to placebo, 120 U NT 201, or 240 U NT-201. Following injection, patients were evaluated at 4 weeks using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). Adverse events (AEs) were also collected up to 20 weeks or until the next injection. The change from Baseline to week 4 for the TWSTRS scores was analyzed using an ANCOVA model.

Results

There were 90 CD patients (67.8% women, mean age 51.1 years, mean CD duration 13.5 months), Patients were randomized to placebo (N= 28), 120 U NT 201 (N= 31), and 240U NT 201 (N=31). The change in total TWSTRS from baseline to week 4 was -2.0 plus or minus 6.0 points (placebo group); -11.9 plus or minus 11.1 points (120 U group) and -10.0 plus or minus 9.2 points ( 240 U group) (p < 0.001 compared to placebo). Improvement in TWSTRS-Severity score from baseline to week 4 was -1.9 plus or minus 4.5 points (placebo group); -4.1 plus or minus 4.3 points (120 U group) and -5.4 plus or minus 5.5 points (240 U group). AEs occurred in 53.6% of patients of the placebo group, in 58.1% of the 120 U group and in 71.0% of the 240 U group. AEs reported most frequently were dysphagia (0% vs 19.4% vs 22.6%), muscular weakness (3.6% vs 6.5% vs 22.6%), and neck pain (3.6% vs 3.2%, vs 22.6%) for each group, respectively.

Third Study - Title

Repeated injections of NT-201 (Xeomin(R); botulinum neurotoxin free from complexing proteins) in upper limb post-stroke spasticity patients authored by P. Kanovsky for the NT 201 Study Group, I. Sassin, G. Comes, S. Grafe, T. Platz

Method

Patients who previously participated in the double-blind, placebo-controlled study, entered the OLEX Period, and were treated with NT-201 (up to five injection intervals) over 1 year (48 to 69 weeks). Parameters were the Ashworth Scale, Disability Assessment Scale (DAS), global assessments, and standard safety testing.

Out of 148 patients who participated in the double-blind period of the study, 145 entered the OLEX Period. 120 patients completed the 1-year trial period. Upper limb muscle groups were treated as clinically indicated (median dose: 400 units, maximum dose: 500 units). Changes on the Ashworth Scale score were highly statistically significant (p < 0.0001; Wilcoxon signed rank test) at control visits during all four injection intervals and in all muscle groups. NT 201 was effective in reducing functional impairment as shown on the DAS (therapeutic domains of hygiene, dressing, limb position, and pain). Efficacy was assessed as very good or good by the majority of investigators, patients and caregivers (range from 56.3% to 85.3%). During the 1-year trial period, adverse events were observed in 56.6% of patients. None of the patients had positive antibody titer tested in the mouse diaphragm assay.

About Merz

Merz (KGAa) is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in research and development of pharmaceuticals for the treatment of neurological and psychological disorders as well as for aesthetic dermatology, including products for the treatment of wrinkles and aging skin, hair loss and acne. Research is concentrated in fields that have a strong need for therapeutic innovation such as Alzheimer's disease, Parkinson's disease, tinnitus, chronic pain conditions, addictions, and neuromuscular disturbances.

Merz Pharmaceuticals, LLC is the wholly owned, US subsidiary of the Merz Group of Companies. A specialty pharmaceutical company, Merz Pharmaceuticals, LLC was established in 1995 and is responsible for the commercialization of Merz (KGAa) products in the US.


'/>"/>
SOURCE Merz Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
2. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
3. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
4. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
5. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
6. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
11. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... 22, 2017  As the latest Obamacare repeal effort ... Cassidy (R-LA) and Lindsey Graham (R-SC) ... medical device industry is in an odd place.  The ... 2.3% excise tax on medical device sales passed along ... covered patients, increased visits and hospital customers with the ...
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
Breaking Medicine News(10 mins):